Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/63121
Authors: 
Sorisio, Enrico
Strøm, Steinar
Year of Publication: 
2006
Series/Report no.: 
Memorandum, Department of Economics, University of Oslo 2006,12
Abstract: 
We have estimated the demand of erythropoietin (EPO) on market data from the Nordic countries. Assuming that prices are set in a Nash-Bertrand game we determine the degree of competition in this Nordic market. We also report the impact of product innovation on welfare, e.g on consumer and producer surplus. The product innovation is the entry of Aranesp in the Nordic market. We find a positive effect related to the introduction of Aranesp in the EPO market. The high increase in consumer surplus however seems not to be accompanied by a great increase in producer surplus, whose growth is slight. Some time after the introduction of the innovation, the surplus growth does not seem to increase, it remains more or less the same (or decreases a bit). An important conclusion in our paper is that although there are few firms competing in the Nordic market for EPO, the estimated long run market power is low.
Subjects: 
Discrete choice
demand for pharmaceuticals
monopolistic competition
EPO
JEL: 
C35
D43
I18
L11
Document Type: 
Working Paper

Files in This Item:
File
Size
408.94 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.